

Chapter 166

Adamantiades–Behçet Disease

Christos C. Zouboulis

REFERENCES

1. McCarty MA, Garton RA, Jorizzo JL: Complex aphthosis and Behçet's disease. *Dermatol Clin* **21**:41, 2003
2. Suzuki Kurokawa M, Suzuki N: Behçet's disease. *Clin Exp Med* **4**:10, 2004
3. Zouboulis CC, Keitel W: A Historical review of early descriptions of Adamantiades–Behçet's disease. *J Invest Dermatol* **119**:201, 2002
4. Zouboulis CC: Epidemiology of Adamantiades–Behçet's disease. In: *Immunology of Behçet's Disease*, edited by M Zierhut, S Ohno. Lisse, Swets & Zeitlinger, 2003, p. 1
5. Azizlerli G et al: Prevalence of Behçet's disease in Istanbul, Turkey. *Int J Dermatol* **42**:803, 2003
6. Altenburg A et al: Epidemiology and clinical manifestations of Adamantiades–Behçet disease in Germany—Current pathogenetic concepts and therapeutic possibilities. *J Dtsch Dermatol Ges* **4**:49, 2006
7. Zouboulis CC, May T: Pathogenesis of Adamantiades–Behçet's disease. *Med Microbiol Immunol* **192**:149, 2003
8. Hirohata S, Kikutchi H: Behçet's disease. *Arthritis Res Ther* **5**:139, 2003
9. de Menthon M et al: HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. *Arthritis Rheum* **61**:1287, 2009
10. Zouboulis CC, Turnbull JR, Martus P: Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades–Behçet's disease. *Adv Exp Med Biol* **528**:123, 2003
11. Fietta P: Behçet's disease: Familial clustering and immunogenetics. *Clin Exp Rheumatol* **23**: (Suppl. 38):S96, 2005
12. Durrani K, Papaliadis GN: The genetics of Adamantiades–Behçet's disease. *Semin Ophthalmol* **23**:73, 2008
13. Zierhut M et al: Immunology and functional genomics of Behçet's disease. *Cell Mol Life Sci* **60**: 1903,2003
14. Remmers EF et al: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. *Nat Genet* **42**: 698, 2010
15. Papoutsis N et al: HLA-antigens and their importance as prognostic-marker in Adamantiades–Behçet's disease (ABD)—Is HLA-Bw4 a new prognostic marker? *Abstracts of the 14th International Conference on Behçet's Disease*, London, UK, 2010, p. 163
16. Escudier M, Bagan J, Scully C: Behçet's disease (Adamantiades syndrome). *Oral Dis* **12**:78, 2006
17. Mizuki N et al: Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. *Nat Genet.* **42**:703, 2010
18. Lee EB et al: Haplotype association of *IL-8* gene with Behçet's disease. *Tissue Antigens* **69**:128, 2007
19. Jiang Z et al: *IL-23R* gene confers susceptibility to Behçet's disease in a Chinese Han population. *Ann Rheum Dis* **69**:1325, 2010
20. Kaneko F et al: The role of infectious agents in the pathogenesis of Behçet's disease. *Adv Exp Med Biol* **528**:181, 2003
21. Zouboulis CC, Turnbull JR, Mühlradt PF: High seroprevalence of anti-*Mycoplasma fermentans* antibodies in patients with malignant aphthosis. *J Invest Dermatol* **121**:211, 2003
22. Neves FS et al: Neutrophil hyperchemotaxis in Behçet's disease: A possible role for monocytes orchestrating bacterial-induced innate immune responses. *Clin Rheumatol* **28**:1403, 2009
23. Gül A: Behçet's disease as an autoinflammatory disorder. *Curr Drug Targets Inflamm Allergy* **4**:81, 2005
24. Yanagihori H et al: Role of IL-12B promoter polymorphism in Adamantiades–Behçet's disease susceptibility: An involvement of Th1 immunoreactivity against *Streptococcus sanguinis* antigen. *J Invest Dermatol* **126**:1534, 2006
25. Freysdottir J et al: Diversity of gd T cells in patients with Behçet's disease is indicative of polyclonal activation. *Oral Dis* **12**:271, 2006

26. Mahesh SP et al: Alpha tropomyosin as a self-antigen in patients with Behçet's disease. *Clin Exp Immunol* **140**:368, 2005
27. Lu Y et al: Identification of kinectin as a novel Behçet's disease autoantigen. *Arthritis Res Ther* **7**:R1133, 2005
28. Direskeneli H, Saruhan-Direskeneli G: The role of heat shock proteins in Behçet's disease. *Clin Exp Rheumatol* **21**:S44, 2003
29. Birtas-Atesoglu E et al: Serum levels of free heat shock protein 70 and anti-HSP70 are elevated in Behçet's disease. *Clin Exp Rheumatol* **26**:(Suppl. 50):S96, 2008
30. Katsantonis J et al: Adamantiades-Behçet's disease: Serum IL-8 is a more reliable marker for disease activity than c-reactive protein and erythrocyte sedimentation rate. *Dermatology* **201**:37, 2000
31. Durmazlar SP et al: Significance of serum interleukin-8 levels in patients with Behçet's disease: High levels may indicate vascular involvement. *Int J Dermatol* **48**:259, 2009
32. Polat M et al: Classifying patients with Behçet's disease for disease severity, using a discriminating analysis method. *Clin Exp Dermatol* **34**:151, 2009
33. Chi W et al: Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. *Invest Ophthalmol Vis Sci* **49**:3058, 2008
34. Habibagahi Z, Habibagahi M, Heidari M: Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease. *Mod Rheumatol* **20**:154, 2010
35. Kalayciyan A, Zouboulis CC: An update on Behçet's disease. *J Eur Acad Dermatol Venereol* **21**:1, 2007
36. Lee KH et al: Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. *Arthritis Rheum* **48**:2025, 2003
37. International Study Group for Behçet's Disease: Criteria for diagnosis of Behçet's disease. *Lancet* **335**:1078, 1990
38. Kaneko F et al: Behçet's disease and diseases for its differential diagnosis in dermatology. An annual report of the Behçet's Disease Research Committee of Japan, 1999, p. 128
39. Schirmer M et al: Evaluation and revision of the International Criteria for Behçet's Disease (ICBD). *Abstracts of the 14th International Conference on Behçet's Disease*, London, UK, 2010, p. 145
40. Davatchi F et al: Validation of the International Criteria for Behçet's disease (ICBD) in Iran. *Int J Rheum Dis* **13**:55, 2010
41. Oh SH et al: Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease. *Clin Exp Dermatol* **34**:e208, 2009
42. Jorizzo JL et al: Mucocutaneous criteria for the diagnosis of Behçet's disease: An analysis of clinicopathologic data from multiple international centers. *J Am Acad Dermatol* **32**:968, 1995
43. Krause L: Morbus Adamantiades-Behçet. *Ophthalmologie* **102**:329, 2005
44. Rogers RS 3rd: Pseudo-Behçet's disease. *Dermatol Clin* **21**:49, 2003
45. Zouboulis CC et al: Current epidemiological data from the German Registry of Adamantiades-Behçet's disease. *Adv Exp Med Biol* **528**:43, 2003
46. Sakamoto M et al: Prognostic factors of vision in patients with Behçet disease. *Ophthalmology* **102**:317, 1995
47. Coskun B, Öztürk P, Saral Y: Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet's disease? *Int J Clin Pract* **59**:69, 2005
48. Zouboulis CC: Adamantiades-Behçet's disease. In: *European Handbook of Dermatological Treatments*, edited by AD Katsambas, TM Lotti, 2nd edition. Berlin Heidelberg, Springer, 2003, p16
49. Alpsoy E: Behçet's disease: Treatment of mucocutaneous lesions. *Clin Exp Rheumatol* **23**:532, 2005
50. Lee JH, Jung JY, Bang D: The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: Comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. *J Eur Acad Dermatol Venereol* **22**:590, 2008
51. Atmaca LS, Yalçındağ FN, Ozdemir O: Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. *Graefes Arch Clin Exp Ophthalmol* **245**:451, 2007
52. Tuncer S et al: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. *J Ocul Pharmacol Ther* **23**:395, 2007
53. Pipitone N et al: New approaches in the treatment of Adamantiades-Behçet's disease. *Curr Opin Rheumatol* **18**:3, 2006
54. Hatemi G et al: Management of Behçet disease: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. *Ann Rheum Dis* **68**:1528, 2009

55. Mat C et al: A double-blind trial of depot corticosteroids in Behçet's syndrome. *Rheumatology (Oxford)* **45**:348, 2006
56. Matsuda T et al: Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: A randomised, double-blind, placebo-controlled study. *Drugs R D* **4**:19, 2003
57. Davatchi F et al: Colchicine versus placebo in Behçet's disease: Randomized, double-blind, controlled crossover trial. *Mod Rheumatol* **19**:542, 2009
58. Yurdakul S et al: A double-blind trial of colchicine in Behçet's syndrome. *Arthritis Rheum* **44**:2686, 2001
59. Aktulga E et al: A double blind study of colchicine in Behçet's disease. *Haematologica* **65**:399, 1980
60. Sharquie KE, Najim RA, Abu-Raghif AR: Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. *J Dermatol* **29**:267, 2002
61. Yazici H et al: A controlled trial of azathioprine in Behçet's disease. *N Engl J Med* **322**:281, 1990
62. Alpsoy E et al: Interferon alfa-2a in the treatment of Behçet's disease: A randomized placebo-controlled and double-blind study. *Arch Dermatol* **138**:467, 2002
63. Kiliç H et al: Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome. *Rheumatology (Oxford)* **48**:1388, 2009
64. Hamuryudan V et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* **128**:443, 1998
65. Masuda K et al: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. *Lancet* **1**(8647):1093, 1989
66. Ozyazgan Y et al: Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. *Br J Ophthalmol* **76**:241, 1992
67. BenEzra D et al: Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. *Transplant Proc* **20**: (Suppl. 4):136, 1988
68. Melikoglu M et al: Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. *J Rheumatol* **32**:98, 2005
69. Davies UM, Palmer RG, Denman AM: Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: A randomized double-blind trial. *Br J Rheumatol* **27**:300, 1988
70. Moral F et al: Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: A randomized, double blind, placebo controlled study. *Clin Exp Rheumatol* **13**:493, 1995
71. Sfikakis PP et al: Anti-TNF therapy in the management of Behçet's disease: Review and basis for recommendations. *Rheumatology (Oxford)* **46**:736, 2007
72. Nanke Y et al: Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: An open-label, single-centre study. *Drugs R D* **9**:455, 2008
73. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behçet's disease with systemic interferon alfa. *Arch Dermatol* **134**:1010, 1998
74. Krause L et al: Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. *J Rheumatol* **35**:896, 2008
75. Guillaume-Czitrom S et al: Efficacy and safety of interferon-alpha in the treatment of corticoid-dependent uveitis of paediatric Behçet's disease. *Rheumatology (Oxford)* **46**:1570, 2007
76. Zouboulis CC: Morbus Adamantiades-Behçet. In: *Cyclosporin in der Dermatologie*, edited by U Mrowietz. Stuttgart, Thieme, 2003, p. 38
77. Niccoli L et al: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. *Rheumatology (Oxford)* **46**:1161, 2007
78. Tognon S, Graziani G, Marcolongo R: Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: Advantages and controversial aspects. *Ann N Y Acad Sci* **1110**:474, 2007
79. Pipitone N A et al: Infliximab for the treatment of Neuro-Behçet's disease: A case series and review of the literature. *Arthritis Rheum* **59**:285, 2008
80. Naganuma M et al: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. *Inflamm Bowel Dis* **14**:1259, 2008
81. Bawazeer A, Raffa LH: Clinical experience with adalimumab in the treatment of ocular Behçet disease. *Ocul Immunol Inflamm* **18**:226, 2010
82. Yasui K et al: Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. *Inflamm Bowel Dis* **14**:396, 2008
83. Davies UM, Palmer RG, Denman AM: Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: A randomized double-blind trial. *Br J Rheumatol* **27**:300, 1988

